About Alector, Inc.
https://www.alector.comAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
CEO
Arnon Rosenthal
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Mizuho
Outperform
William Blair
Market Perform
BTIG
Neutral
Cantor Fitzgerald
Neutral
TD Cowen
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:15.18M
Value:$28.09M
BLACKROCK INC.
Shares:9.1M
Value:$16.84M
BLACKROCK, INC.
Shares:7.2M
Value:$13.32M
Summary
Showing Top 3 of 176
About Alector, Inc.
https://www.alector.comAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.26M ▼ | $40.87M ▼ | $-34.67M ▼ | -1.06K% ▼ | $-0.34 ▼ | $-33.43M ▼ |
| Q2-2025 | $7.87M ▲ | $42.01M ▼ | $-30.52M ▲ | -387.66% ▲ | $-0.3 ▲ | $-30.92M ▲ |
| Q1-2025 | $3.67M ▼ | $48.37M ▲ | $-40.47M ▼ | -1.1K% ▼ | $-0.41 ▼ | $-42.85M ▼ |
| Q4-2024 | $54.24M ▲ | $15.03M ▼ | $-2.07M ▲ | -3.82% ▲ | $-0.02 ▲ | $-5.17M ▲ |
| Q3-2024 | $15.34M | $63.78M | $-42.22M | -275.19% | $-0.44 | $-46.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $291.11M ▼ | $335.29M ▼ | $277.57M ▼ | $57.71M ▼ |
| Q2-2025 | $307.28M ▼ | $356.42M ▼ | $285.25M ▼ | $71.17M ▼ |
| Q1-2025 | $354.55M ▼ | $408.3M ▼ | $313.69M ▼ | $94.61M ▼ |
| Q4-2024 | $413.4M ▼ | $468.3M ▼ | $341.5M ▼ | $126.8M ▲ |
| Q3-2024 | $457.2M | $516.02M | $397.09M | $118.93M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.67M ▼ | $-32.51M ▲ | $49.54M ▼ | $14.7M ▲ | $31.73M ▲ | $-32.52M ▲ |
| Q2-2025 | $-30.52M ▲ | $-49.05M ▲ | $55.72M ▼ | $122K ▲ | $6.8M ▲ | $-49.06M ▲ |
| Q1-2025 | $-40.47M ▼ | $-60.78M ▼ | $65.73M ▲ | $0 ▼ | $4.95M ▲ | $-60.8M ▼ |
| Q4-2024 | $-2.07M ▲ | $-55.03M ▼ | $41.4M ▲ | $9.79M ▲ | $-4.14M ▲ | $-55.2M ▼ |
| Q3-2024 | $-42.22M | $-50.73M | $40.35M | $0 | $-10.39M | $-50.95M |
Revenue by Products
| Product | Q3-2021 |
|---|---|
 Phase Three License | $170.00M ▲ |
CEO
Arnon Rosenthal
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Mizuho
Outperform
William Blair
Market Perform
BTIG
Neutral
Cantor Fitzgerald
Neutral
TD Cowen
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:15.18M
Value:$28.09M
BLACKROCK INC.
Shares:9.1M
Value:$16.84M
BLACKROCK, INC.
Shares:7.2M
Value:$13.32M
Summary
Showing Top 3 of 176